Sanofi expanded its vaccine portfolio by acquiring Dynavax assets, adding a hepatitis B vaccine program and a shingles candidate to its pipeline, according to a deals report. The transaction brings late‑stage and near‑clinical vaccine assets into Sanofi’s broader infectious‑disease strategy. The deal augments Sanofi’s immunization offerings and provides Dynavax shareholders an exit path while enabling Sanofi to integrate the candidates into its global development and commercialization channels. Sanofi’s acquisition reflects continued big‑pharma interest in vaccine assets with established clinical data or near‑term regulatory potential. Strategically, the takeout may accelerate global access planning for the HBV asset and reposition Sanofi in the competitive shingles and hepatitis markets.